Emma Guttman-Yassky, MD, PhD, is the Waldman Professor of Dermatology and Immunology and Health System Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai in New York City. She is the Director of the Occupational Dermatitis Clinic and Director of the Laboratory for Inflammatory Skin Diseases.

Dr. Guttman earned her MD degree from Sackler School of Medicine at the Tel-Aviv University, and a PhD degree from the Bar-Ilan University, Israel. After obtaining her Israeli Board certification in dermatology at Rambam Medical Center/Technion, Israel, Dr. Guttman moved to the U.S. to pursue a two-year postdoctoral fellowship at The Rockefeller University in the Laboratory for Investigative Dermatology. Upon completion of her fellowship, she became board-certified by the American Board of dermatology after a second dermatology residency training at the Weill-Cornell Medical College, in NY. Dr. Guttman’s major clinical and research focus areas are atopic dermatitis (AD)/eczema and alopecia areata. Her research made paradigm-shifting discoveries on the immunologic basis of atopic dermatitis (AD)/eczema in adults and children with atopic dermatitis, enriching the understanding of the pathophysiology of this common disorder, opening the door and accelerating testing of novel immune, pathway-specific drugs in this disease. She is now testing (both clinically and mechanistically) multiple targeted therapeutics for atopic dermatitis that target Th2, Th22, and Th17/IL-23 axis. Recently Dr. Guttman also extended her research interest to hair loss disorders such as alopecia areata and scarring hair loss disorders, chronic hand eczema, keloids, ichtyosis, and other skin diseases, in which her findings are also translated to novel therapeutic targets.

Dr. Guttman is considered one of the world’s leading experts in inflammatory skin diseases. Her achievements have been repeatedly highlighted by the media including the New York Times, ABC News, CBS News, Daily News, Reuters, Wall Street Journal, NY1, and others.

Dr. Guttman divides her time between a busy clinic, where she sees patients from all over the US and the world, that are coming to seek her advise in treating inflammatory skin diseases, and her growing laboratory that focuses on research on the mechanisms underlying inflammatory skin diseases, leading to novel treatments for these patients.

Dr. Guttman co-founded the International Eczema Council (IEC), a global organization of the key opinion leaders in eczema (>100 councilors from all continents) where she served as president from early 2018 though 2021. Dr. Guttman received many national and international awards, including the American Academy of Allergy and Clinical Immunology (AAAAI) Award for Scientific Innovation, and the American Academy of Dermatology Young Investigator award. Most recently she gave the Keynote Lecture: Atopic Dermatitis—The Road to a Personalized Medicine Approach, at the 51st ESDR Annual Meeting in the fall of 2022; and was awarded the Donald Y. M. Leung, MD, PhD, the JACI Editors’ Lectureship and Faculty Development Award, at the 2021 AAAAI Virtual Annual Meeting. Notably, Dr. Guttman and her team received the 2021 Article of the Year Award in Dermatits for “Transcriptomic Profiling of Tape-Strips from Moderate to Severe Atopic Dermatitis Patients Treated With Dupilumab”.

Dr. Guttman serves on the Board of the American Skin Association (ASA) as well as the Medical Advisory Committee of the (ASA) and was elected to the Research Advisory Council, and the National Alopecia Areata foundation (NAAF). She was also elected as a member to the American Society for Clinical Investigation (ASCI), as well as the American Dermatological Society (ADA).

Dr. Guttman is often invited as a keynote speaker to international and national meetings, and has authored ~340 peer-reviewed publications. Dr. Guttman is also the co-organizer of the Inflammatory Skin Disease Summit, that is considered one of the most successful meetings in dermatology.

The state of Florida requires out-of-state professionals who are registered to provide telehealth services to display a hyperlink to the Florida Department of Health telehealth web page. This allows Florida patients who are receiving medical care by telehealth to confirm the provider’s licensure and Florida registration.